You are here

FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI152954-01A1
Agency Tracking Number: R41AI152954
Amount: $262,947.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA19-270
Timeline
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-07-17
Award End Date (Contract End Date): 2022-06-30
Small Business Information
25571 CLAWITER RD
Hayward, CA 94545-2740
United States
DUNS: 052917593
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KEITH WYCOFF
 (510) 887-1461
 kwycoff@planetbiotechnology.com
Business Contact
 ELLIOTT FINEMAN
Phone: (510) 887-1461
Email: efineman@planetbiotechnology.com
Research Institution
 UNIVERSITY OF NORTH DAKOTA
 
264 CENTENNIAL DR, STOP 7306
GRAND FORKS, ND 58202-7306
United States

 Nonprofit college or university
Abstract

Lyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000
cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sensu lato (the
Lyme borreliae), which are transmitted by ticks from animal (bird, rodent) reservoirs to human hosts. While a
short course of antibiotics is usually effective in eliminating the bacteria a sizeable number of LD patients
continue to suffer long-term, debilitating sequelae, including pain, fatigue, cognitive dysfunction and other
symptoms known as post-treatment Lyme disease (PTLD). As many as 1.9 million people in the US suffer from
PTLD. There is currently no vaccine that can prevent LD or PTLD.We are developing an immunoprophylactic for LD and other tick-borne diseases (TBD) based on an
understanding of the virulence mechanisms that the causal pathogens use to evade innate immunity. These
pathogens protect themselves from elimination by the human complement system by binding to the human
complement inhibitor Factor H (FH), a protein abundant in blood. FH bound to bacterial surfaces blocks the
activation of the alternative complement pathway that would otherwise destroy the bacteria. We have produced
recombinant proteins that are fusions of the FH domains that bind to Lyme borreliae with the constant region of
human IgG1 (Fc), using a plant expression system. These fusion proteins (SCR6,7/Fc and SCR(18-20)/Fc) bind
to Lyme borreliae and, in the presence of human complement, kill the bacteria. The Fc gives the proteins a long
half-life, which may allow them to be used as a pre-exposure prophylactic (PrEP) to prevent LD and TBDs.The overall goal of this Phase I SBIR is to demonstrate the efficacy of SCR6,7/Fc and SCR(18-20)/Fc in
preventing Lyme borreliae infection in a mouse model of LD and determine a minimal effective dose. The project
is a collaboration of three research groups that are uniquely qualified to bring it to a successful conclusion. Planet
Biotechnology (the small business concern) will produce SCR6,7/Fc and SCR(18-20)/Fc and two novel Fc
variants of both proteins designed to enhance complement activation. Catherine Brissette at the University of
North Dakota will evaluate the ability of the proteins to mediate complement-dependent killing of Lyme and
relapsing fever spirochetes by membrane attack complex and opsonophagocytosis by human macrophages. Yi-
Pin Lin at the New York State Department of Health will evaluate the ability of the proteins to block infection
when mice are bitten by ticks carrying a virulent Lyme borreliae strain. The mouse experiments are designed to
both identify the most potent SCR6,7/Fc and SCR(18-20)/Fc variant and identify the minimal dose that is 100%
effective in blocking infection when injected 1 day prior to tick challenge. If successful, we will have demonstrated
the commercial potential of an FH/Fc fusion as a PrEP for LD and potentially other TBD.Lyme disease, caused by multiple species of the spirochete Borrelia burgdorferi sensu lato, is
the most common tick-borne disease in the United States. Though acute illness is commonly
treated by antibiotics, prolonged disease manifestations costs the U.S. health care system close
to $1.3 billion a year. We are developing a pre-exposure prophylaxis to prevent LD in individuals
who are at particularly high risk of infection.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government